Graham Capital Management’s Allogene Therapeutics ALLO Stock Holding History

Graham Capital Management’s Portfolio ALLO Stock Details ALLO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$238K	Buy	114,419 +71,155	+164%	+$156K	﹤0.01%	979
2026 Q1	$106K	Sell	43,264 -105,407	-71%	-$211K	﹤0.01%	1035
2025 Q4	$204K	Sell	148,671 -48,637	-25%	-$64.2K	﹤0.01%	1036
2025 Q3	$245K	Sell	197,308 -104,962	-35%	-$125K	﹤0.01%	958
2025 Q2	$342K	Buy	+302,270	New	+$402K	0.01%	949
2025 Q1	–	Sell	-41,737	Closed	-$88.9K	–	1269
2024 Q4	$88.9K	Buy	+41,737	New	+$103K	﹤0.01%	1167
2023 Q3	–	Sell	-62,431	Closed	-$310K	–	997
2023 Q2	$310K	Buy	62,431 +41,525	+199%	+$225K	0.01%	673
2023 Q1	$103K	Buy	+20,906	New	+$134K	﹤0.01%	1001
2022 Q4	–	Sell	-103,895	Closed	-$1.12M	–	1030
2022 Q3	$1.12M	Sell	103,895 -130,975	-56%	-$1.78M	0.04%	435
2022 Q2	$2.68M	Buy	234,870 +91,040	+63%	+$808K	0.11%	134
2022 Q1	$1.31M	Buy	+143,830	New	+$1.5M	0.05%	216

Other funds holding ALLO

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Pfizer New York $170M AUM 191.09% 1-Year Est. Return

FLSM

Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

TGA

TPG GP A Fort Worth, Texas $5B AUM 58.56% 1-Year Est. Return

SCM

Sio Capital Management New York $604M AUM 96.57% 1-Year Est. Return

Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return

Graham Capital Management's ALLO Position: Q2 2026 in Review

Graham Capital Management increased its Allogene Therapeutics (ALLO) stake by 164% in Q2 2026, buying an estimated $156K and bringing the position to 114,419 shares worth $238K. The position accounts for ﹤0.01% of the portfolio, ranked #979.

Graham Capital Management first reported a position in ALLO in Q1 2022 and has held it in 11 quarters since. The position peaked at $2.68M in Q2 2022. 209 funds tracked by Wall St. Rank hold ALLO as of Q2 2026.

Graham Capital Management held 114,419 shares of Allogene Therapeutics worth $238K as of Q2 2026.
Graham Capital Management bought 71,155 Allogene Therapeutics shares in Q2 2026, an estimated $156K.
Allogene Therapeutics made up ﹤0.01% of Graham Capital Management's portfolio in Q2 2026, its #979 holding.
Graham Capital Management first reported a position in Allogene Therapeutics in Q1 2022 and has held it in 11 quarters since.
Graham Capital Management's Allogene Therapeutics position peaked at $2.68M in Q2 2022.
209 funds tracked by Wall St. Rank held Allogene Therapeutics as of Q2 2026.

Based on Graham Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.